ABT vs BMY · P/E 25, rev $44.33B vs P/E 17, rev $24.46B
Abbott Laboratories (ABT) versus Bristol-Myers Squibb Company (BMY) — a side-by-side from cached financials, not a winner call.
Abbott Laboratories (ABT) is a medical devices company listed on NYSE.
Bristol-Myers Squibb Company (BMY) is a drug manufacturers - general company listed on US. It is led by Chris Boerner.
Latest reported ABT revenue for 2025-12-31 was $44.33B. Net income was $6.52B. Revenue was up 5.7% from 2024-12-31 to 2025-12-31. ABT currently screens at market cap $154.15B and trailing P/E 24.8.
Latest reported BMY revenue for 2026-06-30 was $24.46B. Net income was $5.99B. BMY currently screens at market cap $95.36B and trailing P/E 17.5.
ABT currently screens at market cap $154.15B and trailing P/E 24.8. BMY currently screens at market cap $95.36B and trailing P/E 17.5.
Not investment advice. Open the ABT and BMY stock pages for the full models.
Not investment advice.